Oppenheimer Cuts Zura Bio (NASDAQ:ZURA) Price Target to $15.00

Zura Bio (NASDAQ:ZURA) had its target price lowered by Oppenheimer from $16.00 to $15.00 in a research report released on Friday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

ZURA has been the topic of several other research reports. Wedbush began coverage on shares of Zura Bio in a research note on Monday, February 9th. They issued an “outperform” rating and a $15.00 price objective on the stock. Leerink Partners upgraded shares of Zura Bio to a “strong-buy” rating in a report on Sunday, November 23rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research note on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.40.

Zura Bio Price Performance

NASDAQ:ZURA opened at $5.50 on Friday. Zura Bio has a fifty-two week low of $0.97 and a fifty-two week high of $7.44. The stock’s 50-day moving average is $6.17 and its two-hundred day moving average is $4.57. The stock has a market cap of $357.61 million, a PE ratio of -5.19 and a beta of 0.18.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.31). On average, equities research analysts anticipate that Zura Bio will post -0.65 earnings per share for the current year.

Insiders Place Their Bets

In other Zura Bio news, major shareholder Ai Biotechnology Llc acquired 2,000,000 shares of the business’s stock in a transaction that occurred on Thursday, February 26th. The shares were purchased at an average price of $6.25 per share, with a total value of $12,500,000.00. Following the completion of the transaction, the insider owned 6,552,725 shares in the company, valued at $40,954,531.25. The trade was a 43.93% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 22.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Allworth Financial LP bought a new position in shares of Zura Bio during the 4th quarter valued at $30,000. Savant Capital LLC boosted its holdings in Zura Bio by 190.4% in the second quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock worth $34,000 after purchasing an additional 21,249 shares in the last quarter. Scientech Research LLC acquired a new position in Zura Bio during the third quarter worth $45,000. AQR Capital Management LLC bought a new position in Zura Bio during the first quarter valued at about $72,000. Finally, Forefront Wealth Partners LLC bought a new position in Zura Bio during the third quarter valued at about $93,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.